source
- Sanofi pauses phase 2 bronchiectasis trial of SAR445399 for strategic reasonsSanofi has halted a phase 2 study of its monoclonal antibody SAR445399 in adults with non‑cystic fibrosis bronchiectasis. The trial, which began in April, was a randomized, double‑blind, placebo‑co…
- AstraZeneca and Bristol Myers Squibb abandon merger talksReuters reported that AstraZeneca and Bristol Myers Squibb have ended discussions about a possible merger and will not pursue a deal. The collapse of the talks removes a potential consolidation th…